Phosphodiesterase 7A (PDE7A) mRNA (PDE7A mRNA)

Phosphodiesterase 7A (PDE7A) mRNA is the messenger RNA transcript that encodes the PDE7A enzyme, a high-affinity, cAMP-specific phosphodiesterase primarily expressed in T-lymphocytes, the brain, and skeletal muscle [1]. As a therapeutic target, PDE7A mRNA is addressed using RNA-based strategies such as RNA interference (RNAi) or antisense oligonucleotides to selectively downregulate the expression of the PDE7A protein [2]. By reducing the levels of the PDE7A enzyme, intracellular cyclic adenosine monophosphate (cAMP) concentrations are maintained or increased, which subsequently suppresses pro-inflammatory cytokine production and T-cell proliferation [3]. This mechanism makes PDE7A mRNA an attractive target for the treatment of autoimmune and inflammatory conditions, including multiple sclerosis, asthma, and chronic obstructive pulmonary disease (COPD) [4]. Furthermore, its expression in the central nervous system suggests potential therapeutic roles in neurodegenerative diseases like Alzheimer's and Parkinson's [5]. While small molecule inhibitors of the PDE7A protein have been developed, targeting the mRNA offers a highly specific approach to modulating cAMP signaling pathways while potentially minimizing the off-target effects associated with broad-spectrum phosphodiesterase inhibition [6]. Sources: [1] UniProt (Q13946); [2] PubMed (PMID: 15123594); [3] PubMed (PMID: 10449287); [4] PubMed (PMID: 12489574); [5] PubMed (PMID: 24635425); [6] PubMed (PMID: 15837305).

Other names

HCP1 mRNAHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A mRNAPDE7 mRNA transcript

RNA interference (RNAi) leading to mRNA degradation or antisense-mediated inhibition of translation.